期刊文献+

血管活性肠肽和神经肽Y在肾上腺嗜铬细胞瘤中的表达及意义 被引量:1

下载PDF
导出
摘要 目的探讨神经肽Y(neuropeptide Y,NPY)和血管活性肠肽(vasocative intestinal peptide,VIP)在肾上腺嗜铬细胞瘤组织中的表达与肾上腺嗜铬细胞瘤的关系。方法采用免疫组化SP法和图像分析技术对8例正常肾上腺组织20例肾上腺嗜铬细胞瘤中NPY和VIP进行检测。结果免疫组织化学结果显示,NPY,VIP在肾上腺嗜铬细胞瘤中阳性细胞面积、灰度与正常肾上腺组织比较差异有显著性(P<0.01)。NPY,VIP与尿儿茶酚胺(catecholamine,CA)存在正相关关系。结论NPY,VIP在肾上腺嗜铬细胞瘤发生发展中可能有重要意义,可能代表肾上腺嗜铬细胞瘤的分子基础,这可能是治疗和诊断AMH新的靶点。
出处 《广东医学》 CAS CSCD 北大核心 2008年第4期606-607,共2页 Guangdong Medical Journal
基金 广东省重点科技计划项目(编号:2005B30501011)
  • 相关文献

参考文献8

  • 1CAVADAS C, SILVA A P, MOSIMANN F, et al. NPY regulates catecholamine secretion from human adrenal chromaffin cells [ J ]. J Clin Endocrin Metab, 2001, 86(12) : 5 956 -5 963.
  • 2FAHRENKRUG J, BUHL T, HANNIBAL J. PreproPACAP - derived peptides occur in VIP - producing tumors and co - exist with VIP[J]. Regul Pept, 1995, 22(7) : 89 -98.
  • 3GASPO R, LAMARCHE L, DECHAMPLAIN J, et al. Canine adrenal catecholamine response to VIP is blocked by PACAP(6-27) in vivo[J]. AmJ Physiol, 1997, 272(5Pt2) : R1 606-R1 612.
  • 4MAZZOCCHI G, MALENDOWICZ L K, REBUFFAT L, et al. Nussdorfer. The impact of the human genome on endocrinology: original articles[J]. J Clin Endocrinol Metabol, 2002, 87(6): 2 575 -2 580.
  • 5REUBI J C, GUGGER M, WASER B, et al. Y1 - mediated effect of neuropeptide Y in cancer: breast carcinomas as targets [ J]. Cancer Res, 2001, 61(4) : 4 636 -4 641.
  • 6KORNER M, WASER B, REUBI J C. Neuropeptide Y receptor expression in human primary ovarian neoplasms [ J ]. Lab Invest, 2004, 84(8) : 71 -80.
  • 7REUBI J C, GUGGER M, WASER B. Coexpressed peptide receptors in breast cancers as molecular basis for in vivo mtdtireceptor tumor targeting[J]. Eur J Nucl Med, 2002, 29(2) : 855 -862.
  • 8REUBI J C. Peptide receptors as molecular targets for cancer diagnosis and therapy [ J ]. Endocr Rev, 2003,24 ( 10 ) : 389 - 427.

同被引文献10

  • 1王伟,李伟毅.血管活性肠肽的免疫调节作用[J].细胞生物学杂志,2005,27(2):148-152. 被引量:15
  • 2Snoussi K, Strosberg AD, Ben Ahmed S, et al. Genetic variation in pro-inflammatory cytokines ( interleukin-1 beta, interleukin-1 alpha and interleukin-6) associated with the aggressive forms, survival, and relapse prediction of breast carcinoma. Eur Cytokine Netw, 2005,16: 253-260.
  • 3Kim SW, Beauchamp RD, Townsend CM, et al. Vasoactive intestinal polypeptide inhibits c-myc expression and growth of human gastric carcinoma cells. Surgery, 1991,110:270-276.
  • 4lishi H, Tatsuta M, Baba M, et al. Enhancement by vaso-active intestinal peptide of gastric carcinogenesis induced by N-methy1-N'- nitro-N-nitrosoguanidine in rats. Int J Cancer, 1992,50 : 649-652.
  • 5Li GH, Qian W, Song GQ, et al. Effect of vasoactive intestinal peptide on gastric adenocarcinoma. J Gastroenterol Hepatol, 2007,22 : 1328- 1335.
  • 6Nagakawa O, Murata J, Junicho A, et al. Vasoactive intestinal, peptide (VIP) enhances the cell motility of androgen receptor-transfected DU- 145 prostate cancer cells ( DU- 145/AR). Cancer Lett, 2002, 176 : 93- 99.
  • 7Pence JC, Shorter NA. In vitro differentiation of human neuroblastoma cells caused by vasoactive intestinal peptide. Cancer Res, 1990,50 : 5177-5183.
  • 8黄立锋,姚咏明,盛志勇.树突状细胞与调节性T细胞相互作用研究进展[J].中国病理生理杂志,2008,24(3):610-616. 被引量:16
  • 9史育红,谭天秩.血管活性肠肽受体研究现状[J].国外医学(放射医学核医学分册),1998,22(4):148-152. 被引量:13
  • 10巩兰波,王孟春,陈澄,延锦春,姜若兰.血管活性肠肽对胰腺癌细胞的生长调控[J].世界华人消化杂志,2002,10(5):562-565. 被引量:2

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部